130 Results A cohort of 392 patients with sarcoidosis was screened. They all received infliximab treatment for at least 3 months at the St. Antonius Hospital. 261 sarcoidosis patients were excluded due to lack of a PET-scan in more than 14 days after or 90 days before treatment initiation. Another 33 sarcoidosis patients were excluded due to less than 2 SFNSL-scores within one treatment period. 16 patients were excluded due to an SFNSL-score below 11 around treatment initiation. In addition, 46 patients were excluded due to a gap of more than 14 days between treatment initiation and SFNSL-score. Finally, 36 sarcoidosis patients were eligible for analysis, depicted in Figure 1. Figure 4 Results of exclusion criteria SFNSL scores were collected with a mean of 2 days (±6.9) after treatment initiation and the most recent score with a mean of 832 days (±735). When analyzing the relation between time and SFNSL change, no correlation could be found (p=0.508; r=0.114). SUVmax data were collected with a mean of 31 days (±25) before treatment initiation and the most recent data with a mean of 878 days (±662) after treatment initiation. An overview of baseline characteristics of participants is displayed in Table 1. 8 136 8
RkJQdWJsaXNoZXIy MjY0ODMw